• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    HL-507 First-Line brentuximab vedotin plus chemotherapy improves overall survival in patients with stage III/IV classical Hodgkin Lymphoma: an updated analysis of ECHELON-1

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Straus, D.
    Radford, John A
    Connors, J.
    Kim, W. S.
    Gallamini, A.
    Ramchandren, R.
    Friedberg, J.
    Advani, R.
    Hutchings, M.
    Evens, A.
    Smolewski, P.
    Savage, K.
    Bartlett, N.
    Eom, H. S.
    Abramson, J.
    Dong, C.
    Campana, F.
    Fenton, K.
    Puhlmann, M.
    Ansell, S.
    Show allShow less
    Affiliation
    Memorial Sloan Kettering Cancer Center, New York, USA
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Context: Overall survival (OS) benefi t from upfront treatment with new over existing approaches has never been shown in fi rst line (1L) classical Hodgkin lymphoma (cHL). With newer therapies for relapsed/refractory disease, demonstrating improved OS with 1L therapy has been challenging. In ECHELON-1 (NCT01712490), 5-year follow- up analyses supported a long-term progression-free survival (PFS) benefi t with 1L brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with stage Ill/ IV cHL. A+AVD had a manageable long-term safety profi le, with fewer second malignancies and more pregnancies reported vs ABVD (Connors et al, NEJM 2018; Straus et al, Lancet Haematol 2021). We report a prespecifi ed OS analysis after approximately 6 years’ follow-up. Interventions: Patients were randomized 1:1 to receive up to 6 cycles of A+AVD (n=664) or ABVD (n=670) on day 1 and 15, every 28 days. Main Outcomes Measures: OS was the key prespecifi ed secondary endpoint. Results: At a median follow-up of 73 months, 39 and 64 deaths occurred in A+AVD and ABVD arms, respectively; OS signifi cantly favored A+AVD (hazard ratio [HR] 0.590; 95% confi dence interval [Cl] 0.396–0.879; p = 0.009). Estimated 6-year OS rates (95% Cl) were 93.9% (91.6– 95.5) vs 89.4% (86.6–91.7) with A+AVD vs ABVD, respectively, with a consistently higher OS across prespecifi ed subgroups. The 6-year PFS estimate was 82.3% (79.1–85.0) vs 74.5% (70.8–77.7) with A+AVD vs ABVD, respectively (HR 0.678 [95% Cl 0.532– 0.863]). Overall, A+AVD and ABVD had comparable long-term safety profi les. By the last follow-up, 86% (379/443) of treatment related peripheral neuropathy cases in the A+AVD arm and 87% (249/286) in the ABVD arm either completely resolved (72% vs 79%, respectively) or were improving (14% vs 8%, respectively). Fewer second malignancies (23 vs 32) and more pregnancies (49 vs 28) were reported in the A+AVD vs ABVD arm, respectively. No new safety signals were identifi ed. Conclusions: In this updated analysis, A+AVD treatment resulted in a 41% reduction in risk of death vs ABVD, with a manageable safety profi le. These outcomes are important in advancing treatment of patients with previously untreated stage Ill/IV cHL.
    Citation
    Straus D, Radford J, Connors J, Kim WS, Gallamini A, Ramchandren R, et al. HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S350. PubMed PMID: 36164033. Epub 2022/09/28. eng.
    Journal
    Clinical Lymphoma, Myeloma and Leukemia
    URI
    http://hdl.handle.net/10541/625687
    DOI
    10.1016/s2152-2650(22)01483-5
    Additional Links
    https://dx.doi.org/10.1016/s2152-2650(22)01483-5
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/s2152-2650(22)01483-5
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.